PharmVar GeneFocus: CYP2B6

被引：47

作者：

Desta, Zeruesenay ^{[1
]}

El-Boraie, Ahmed ^{[2
,3
,4
]}

Gong, Li ^{[5
]}

Somogyi, Andrew A. ^{[6
]}

Lauschke, Volker M. ^{[7
]}

Dandara, Collet ^{[8
,9
]}

Klein, Kathrin ^{[10
,11
]}

Miller, Neil A. ^{[12
,13
]}

Klein, Teri E. ^{[5
]}

Tyndale, Rachel F. ^{[2
,3
,4
]}

Whirl-Carrillo, Michelle ^{[5
]}

Gaedigk, Andrea ^{[14
,15
]}

机构：

[1] Indiana Univ Sch Med, Divis Clin Pharmacol, Indianapolis, IN USA

[2] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON ON M5S, Canada

[3] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON ON M5S, Canada

[4] Univ Toronto, Dept Psychiat, Toronto, ON ON M5S, Canada

[5] Stanford Univ, Dept Biomed Data Sci, Stanford, CA USA

[6] Univ Adelaide, Adelaide Med Sch, Discipline Pharmacol, Adelaide, SA, Australia

[7] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden

[8] Univ Cape Town, Fac Hlth Sci, Dept Pathol, Div Human Genet, Cape Town, South Africa

[9] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Cape Town, South Africa

[10] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[11] Univ Tubingen, Tubingen, Germany

[12] Childrens Mercy, Gen Med Ctr, Kansas City, MO 64108 USA

[13] Univ Missouri Kansas City, Schl Med, Kansas City, MO 64108 USA

[14] Childrens Mercy, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO 64108 USA

[15] Univ Missouri Kansas City, Sch Med, Kansas City, MO 64110 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 110卷 / 01期

基金：

美国国家卫生研究院; 瑞典研究理事会; 新加坡国家研究基金会; 英国医学研究理事会;

关键词：

SINGLE-NUCLEOTIDE POLYMORPHISM; GENOME-WIDE ASSOCIATION; CYTOCHROME P4502B6; HEPATIC CYP2B6; EFAVIRENZ PHARMACOKINETICS; DEVELOPMENTAL EXPRESSION; BUPROPION HYDROXYLATION; GENETIC POLYMORPHISMS; PLASMA EXPOSURE; CYP2B6-ASTERISK-6;

D O I：

10.1002/cpt.2166

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP2B6 gene. Genetic variation within the CYP2B6 gene locus impacts the metabolism or bioactivation of clinically important drugs. Of particular importance are efficacy and safety concerns regarding: efavirenz, which is used for the treatment of HIV type-1 infection; methadone, a mainstay in the treatment of opioid use disorder and as an analgesic; ketamine, used as an antidepressant and analgesic; and bupropion, which is prescribed to treat depression and for smoking cessation. This GeneFocus provides a comprehensive overview and summary of CYP2B6 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).

引用

页码：82 / 97

页数：16

共 100 条

[1] Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism [J].

Al Koudsi, N. ;

Tyndale, R. F. .

XENOBIOTICA, 2010, 40 (06) :381-392

[2] A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation [J].

Ariyoshi, N ;

Miyazaki, M ;

Toide, K ;

Sawamura, Y ;

Kamataki, T .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (05) :1256-1260

[3] Q172H Replacement Overcomes Effects on the Metabolism of Cyclophosphamide and Efavirenz Caused by CYP2B6 Variant with Arg262 [J].

Ariyoshi, Noritaka ;

Ohara, Miyuki ;

Kaneko, Mayumi ;

Afuso, Sakino ;

Kumamoto, Takuya ;

Nakamura, Hiroyoshi ;

Ishii, Itsuko ;

Ishikawa, Tsutomu ;

Kitada, Mitsukazu .

DRUG METABOLISM AND DISPOSITION, 2011, 39 (11) :2045-2048

[4] Artemisinin-A Possible CYP2B6 Probe Substrate? [J].

Asimus, Sara ;

Ashton, Michael .

BIOPHARMACEUTICS & DRUG DISPOSITION, 2009, 30 (05) :265-275

[5] Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations [J].

Ayuso, Pedro ;

Neary, Megan ;

Chiong, Justin ;

Owen, Andrew .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (11) :3281-3290

[6] Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state [J].

Benowitz, Neal L. ;

Zhu, Andy Z. X. ;

Tyndale, Rachel F. ;

Dempsey, Delia ;

Jacob, Peyton, III .

PHARMACOGENETICS AND GENOMICS, 2013, 23 (03) :135-141

[7] Long-Distance Phasing of a Tentative "Enhancer" Single-Nucleotide Polymorphism With CYP2D6 Star Allele Definitions [J].

Boone, Erin C. ;

Wang, Wendy Y. ;

Gaedigk, Roger ;

Cherner, Mariana ;

Berard, Anick ;

Leeder, J. Steven ;

Miller, Neil A. ;

Gaedigk, Andrea .

FRONTIERS IN PHARMACOLOGY, 2020, 11

[8] PharmVar GeneFocus: CYP2C19 [J].

Botton, Mariana R. ;

Whirl-Carrillo, Michelle ;

Del Tredici, Andria L. ;

Sangkuhl, Katrin ;

Cavallari, Larisa H. ;

Agundez, Jose A. G. ;

Duconge, Jorge ;

Lee, Ming Ta Michael ;

Woodahl, Erica L. ;

Claudio-Campos, Karla ;

Daly, Ann K. ;

Klein, Teri E. ;

Pratt, Victoria M. ;

Scott, Stuart A. ;

Gaedigk, Andrea .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (02) :352-366

[9] Variants in the CYP2B6 3UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs [J].

Burgess, Kimberly S. ;

Ipe, Joseph ;

Swart, Marelize ;

Metzger, Ingrid F. ;

Lu, Jessica ;

Gufford, Brandon T. ;

Thong, Nancy ;

Desta, Zeruesenay ;

Gaedigk, Roger ;

Pearce, Robin E. ;

Gaedigk, Andrea ;

Liu, Yunlong ;

Skaar, Todd C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (01) :130-138

[10]

CHANG TKH, 1993, CANCER RES, V53, P5629

← 1 2 3 4 5 6 7 8 9 10 →